Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study

Peyronnet, B.; Castel-Lacanal, É.; Roumiguié, M.; Even, L.; Marqué, P.; Soulié, M.; Rischmann, P.; Gamé, X.

doi:10.1002/nau.23009

Cited by 17 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another animal model study, Oliveira et al found that OTA was 1.6 times more potent than ATA . Another recent study proposed a ratio between 1:2.5 and 1:3.75 in the human neurogenic bladder, as 750 U ATA were found to be more efficacious than 200 U OTA, but not more efficacious than 300 U OTA . As the controversy of the dose‐equivalence between the two toxins remains unsolved, it has been suggested that a difference in dose equivalence could explain the good results obtained with BTA switch.…”

Section: Discussionmentioning

confidence: 99%

“…27 Another recent study proposed a ratio between 1:2.5 and 1:3.75 in the human neurogenic bladder, as 750 U ATA were found to be more efficacious than 200 U OTA, but not more efficacious than 300 U OTA. 29 As the controversy of the dose-equivalence between the two toxins remains unsolved, 21,22 it has been suggested that a difference in dose equivalence could explain the good results obtained with BTA switch. The association between dose of ATA injected and success of the toxin switch observed in our study supports | 295 this latter hypothesis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Bottet

Peyronnet

Boissier

et al. 2017

Neurourology and Urodynamics

Self Cite

View full text Add to dashboard Cite

Aims: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). Methods: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC). Results: Fifty-seven patients were included. After the first injection of Dysport®, no adverse events were reported. A significant decrease in number of urinary incontinence episodes per day was observed in 52.63% of patients (P < 0.001) and all patients experienced a reduction in PDET Max (−8.1 cmH20 on average; P = 0.003). MCC significantly increased by a mean of 41.2 (P = 0.02). The proportion of patients with no UDC increased significantly at week 6 after ATA injections (from 15.79% to 43.9%; P = 0.0002). Hence, 32 patients draw clinical and/or urodynamic benefits from the botulinum toxin switch from (56.14%). After a median follow up of 21 months, 87% of responders to BTA switch were still treated successfully with BTA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Bottet

Peyronnet

Boissier

et al. 2017

Neurourology and Urodynamics

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 The results of ABO injections for managing the OAB/ DO are comparable to those from ONA. 18,19,21,25 Most trials reporting ABO injections in neurogenic OAB have considered 500 U as the starting dose. 17 [18][19][20] Better results using higher doses of ABO were observed.…”

Section: Discussionmentioning

confidence: 99%

“…In urology, onabotulinumtoxinA and abobotulinumtoxinA are the two most commonly used formulations, the first one being the only licensed one in the USA and Europe for NDO and IDO management . However, randomized clinical trials support the use of ABO for NDO, and small uncontrolled studies have reported its use in IDO/OAB …”

Section: Introductionmentioning

confidence: 99%

“…5,15,16 However, randomized clinical trials support the use of ABO for NDO, and small uncontrolled studies have reported its use in IDO/OAB. [17][18][19][20][21][22][23][24][25][26] These toxins are manufactured throught different processes, resulting in different formulations and not interchangeable doses. The issue of the dose equivalence between ONA and ABO has been intensely debated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder

Bezerra

Toledo

Carramão

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims To compare 300 U versus 500 U of abobotulinumtoxinA (ABO) intravesical injections for the treatment of idiopathic overactive bladder (OAB) refractory to first and second‐line treatments. Methods A prospective, randomized, single blind study was performed in female patients with symptoms of OAB, who had failed conservative treatment. Patients were treated with 300 or 500 U of ABO injected into 30 sites, avoiding the trigone. All treatments were evaluated by voiding diary, ICIQ‐OAB questionnaire, urodynamic test, visual analogue scale (VAS) for treatment satisfaction and patient global impression of improvement (PGI‐I). The primary outcome was change in maximum cistometric capacity (MCC). Secondary outcome included changes in urgency, complete continence, subjective success (VAS and PGI‐I), and adverse events (urinary retention, UTI, and CIC). Results Twenty‐one patients were included. MCC has increased from 185.0 to 270.9 mL (300 U) and from 240.8 to 311.7 mL (500 U), comparing the baseline with 12 weeks, without statistical difference between the groups (P = 0.270). At 12 weeks, 91% of patients were dry in both groups. At 24 weeks, episodes of incontinence had returned in 50% (300 U) and 0% (500 U) (P = 0.013). Patients were better or much better (PGI‐I) in70% (300 U) and 88.9% (500 U) at 12 w; and 50% (300 U) and 100% (500 U), at 24 w (P = 0.027). The peak of PVR was at 4 w, being 71.7 mL (300 U) and 96.5 mL (500 U). General UTI incidence was 35.7%. One patient (500 U) required CIC for 2 weeks. Conclusions Intravesical ABO injection at 500 U improves symptoms and quality of life for longer period of time than 300 U for idiopathic OAB.

show abstract

Failures and long‐term discontinuations of intradetrusor botulinum toxin injections for neurogenic detrusor overactivity: A new challenge in neurourology

Peyronnet

Gamé

2017

Neurourology and Urodynamics

Self Cite

View full text Add to dashboard Cite

Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study

Cited by 17 publications

References 26 publications

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed

A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder

Failures and long‐term discontinuations of intradetrusor botulinum toxin injections for neurogenic detrusor overactivity: A new challenge in neurourology

Contact Info

Product

Resources

About